These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 33692796)

  • 1. From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the Past.
    Shadbad MA; Hajiasgharzadeh K; Derakhshani A; Silvestris N; Baghbanzadeh A; Racanelli V; Baradaran B
    Front Immunol; 2021; 12():623639. PubMed ID: 33692796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic gene modified cell based cancer vaccines.
    Kozłowska A; Mackiewicz J; Mackiewicz A
    Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma.
    Butterfield LH; Vujanovic L; Santos PM; Maurer DM; Gambotto A; Lohr J; Li C; Waldman J; Chandran U; Lin Y; Lin H; Tawbi HA; Tarhini AA; Kirkwood JM
    J Immunother Cancer; 2019 Apr; 7(1):113. PubMed ID: 31014399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted siRNA silencing of indoleamine 2, 3-dioxygenase in antigen-presenting cells using mannose-conjugated liposomes: a novel strategy for treatment of melanoma.
    Chen D; Koropatnick J; Jiang N; Zheng X; Zhang X; Wang H; Yuan K; Siu KS; Shunnar A; Way C; Min WP
    J Immunother; 2014; 37(2):123-34. PubMed ID: 24509175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosuppressive factor blockade in dendritic cells via siRNAs results in objective clinical responses.
    Sioud M; Mobergslien A; Sæbøe-Larssen S
    Methods Mol Biol; 2015; 1218():269-76. PubMed ID: 25319657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving Dendritic Cell Cancer Vaccine Potency Using RNA Interference.
    Sæbøe-Larssen S; Sioud M
    Methods Mol Biol; 2020; 2115():249-258. PubMed ID: 32006405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma.
    De Keersmaecker B; Claerhout S; Carrasco J; Bar I; Corthals J; Wilgenhof S; Neyns B; Thielemans K
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendritic cell based antitumor vaccination: impact of functional indoleamine 2,3-dioxygenase expression.
    Wobser M; Voigt H; Houben R; Eggert AO; Freiwald M; Kaemmerer U; Kaempgen E; Schrama D; Becker JC
    Cancer Immunol Immunother; 2007 Jul; 56(7):1017-24. PubMed ID: 17195079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab.
    Bjoern J; Iversen TZ; Nitschke NJ; Andersen MH; Svane IM
    Cytotherapy; 2016 Aug; 18(8):1043-1055. PubMed ID: 27378345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
    Seledtsov VI; Goncharov AG; Seledtsova GV
    Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma.
    Schadendorf D; Paschen A; Sun Y
    Immunol Lett; 2000 Sep; 74(1):67-74. PubMed ID: 10996630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineering better immunotherapies via RNA interference.
    Sioud M
    Hum Vaccin Immunother; 2014; 10(11):3165-74. PubMed ID: 25483669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate.
    Salcedo M; Bercovici N; Taylor R; Vereecken P; Massicard S; Duriau D; Vernel-Pauillac F; Boyer A; Baron-Bodo V; Mallard E; Bartholeyns J; Goxe B; Latour N; Leroy S; Prigent D; Martiat P; Sales F; Laporte M; Bruyns C; Romet-Lemonne JL; Abastado JP; Lehmann F; Velu T
    Cancer Immunol Immunother; 2006 Jul; 55(7):819-29. PubMed ID: 16187085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysregulated NF-κB-Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma.
    Maurer DM; Adamik J; Santos PM; Shi J; Shurin MR; Kirkwood JM; Storkus WJ; Butterfield LH
    Cancer Immunol Res; 2020 Dec; 8(12):1554-1567. PubMed ID: 33051240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma.
    Wang Y; Zhang L; Xu Z; Miao L; Huang L
    Mol Ther; 2018 Feb; 26(2):420-434. PubMed ID: 29249397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma.
    Geskin LJ; Damiano JJ; Patrone CC; Butterfield LH; Kirkwood JM; Falo LD
    Melanoma Res; 2018 Jun; 28(3):211-221. PubMed ID: 29543704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy.
    Holtzhausen A; Zhao F; Evans KS; Tsutsui M; Orabona C; Tyler DS; Hanks BA
    Cancer Immunol Res; 2015 Sep; 3(9):1082-95. PubMed ID: 26041736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines.
    Vreeland TJ; Clifton GT; Herbert GS; Hale DF; Jackson DO; Berry JS; Peoples GE
    Expert Rev Clin Immunol; 2016 Dec; 12(12):1347-1357. PubMed ID: 27323245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells.
    Carreno BM; Magrini V; Becker-Hapak M; Kaabinejadian S; Hundal J; Petti AA; Ly A; Lie WR; Hildebrand WH; Mardis ER; Linette GP
    Science; 2015 May; 348(6236):803-8. PubMed ID: 25837513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.